Study Reports Link Between Alzheimer’s Cellular Abnormalities

Neurogenetics, Inc. has reported that a study published in the September issue of Neuron links a new mechanism-based therapeutic approach, licensed by the Company from Massachusetts General Hospital (MGH), to Alzheimer’s disease (AD). Researchers from the MGH Genetics and Aging Unit report that they have discovered a key link between two cellular abnormalities associated with Read more about Study Reports Link Between Alzheimer’s Cellular Abnormalities[…]

Alzheimer’s Treatment Granted FDA Approval

The U.S. FDA has granted Novartis Pharmaceuticals Corporation marketing clearance for Exelon (rivastigmine tartrate) capsules, a cholinesterase inhibitor for the treatment of mild to moderate Alzheimer’s disease. Exelon therapy is proven effective in multiple phase III trials in the three key domains used to assess the disease — global functioning (including activities of daily living Read more about Alzheimer’s Treatment Granted FDA Approval[…]

Curagen And Gemini Enter Genome Wide Drug Target Discovery And Pharmacogenetics Collaboration

CuraGen Corporation, an integrated genomics based drug discovery and development company, and Gemini Genomics plc, announced today the largest collaboration to date linking cSNPs (human genetic variations) and clinical information to identify and validate novel drug targets for use in the discovery and development of pharmaceutical and diagnostic products. Specifically, CuraGen and Gemini scientists will Read more about Curagen And Gemini Enter Genome Wide Drug Target Discovery And Pharmacogenetics Collaboration[…]

Roche And deCODE Genetics Identify Schizophrenia Gene

Roche and deCODE genetics have announced that scientists at deCODE together with psychiatrists from the Icelandic healthcare system have identified a gene linked to schizophrenia. This discovery is the result of a genome-wide screen conducted with the participation of 400 Icelandic schizophrenia patients and an equal number of their unaffected family members. The study marks Read more about Roche And deCODE Genetics Identify Schizophrenia Gene[…]

Merck Completes Acquisition Of Sibia

Merck & Co., Inc. has announced that its wholly owned subsidiary, MC Subsidiary Corp., has acquired SIBIA Neurosciences, Inc. by completing its previously announced merger with SIBIA. MC Subsidiary Corp. completed in September a tender offer in which it purchased approximately 69 percent of the outstanding common stock of SIBIA for $8.50 per share. As Read more about Merck Completes Acquisition Of Sibia[…]

Genzyme, AGTC Announce Gene Therapy Collaboration

Genzyme Corporation and Applied Genetic Technologies (AGTC), a private development-stage biotechnology company, announced today that they have entered into a research collaboration to jointly develop novel therapeutics involving gene therapy.Through the collaboration, Genzyme gains access to AGTC’s extensive expertise using Adeno-Associated Virus (AAV) vectors to deliver genes to patients, including access to AGTC’s novel high-yield Read more about Genzyme, AGTC Announce Gene Therapy Collaboration[…]

Antares Pharma NPMG Alliance For Topical Anesthetic

Antares Pharma, Inc. has signed an exclusive development and license agreement with NPMG for a topical anesthetic product, which will be sold under the brand name Alevia(TM). The product will be based on Antares Pharma’s proprietary ATD(TM) gel technology, and will contain lidocaine and tetracaine at low levels to allow distribution and use without a Read more about Antares Pharma NPMG Alliance For Topical Anesthetic[…]

Drug Delivery Device Supply Agreement For Boston Life Sciences And Codman & Shurtleff

Boston Life Sciences, Inc. has announced it has entered into an agreement with Codman & Shurtleff, Inc., a Johnson & Johnson subsidiary, related to BLSI’s development of Inosine for stroke. Under the agreement, Codman will supply BLSI with implantable pumps and catheters for BLSI’s preclinical and clinical studies for Inosine, and in exchange, Codman will Read more about Drug Delivery Device Supply Agreement For Boston Life Sciences And Codman & Shurtleff[…]

Meridian Agrees License Deal With Corixa

Meridian Bioscience, Inc., will begin production of recombinant Trypanosoma cruzi (Chagas’ disease) antigen under a license agreement with Corixa Corporation. Manufacture will take place in its life science production laboratories located at Viral Antigens, Inc., (VAI), a wholly owned subsidiary. The unique recombinant polyvalent antigen, known as TcF, will be marketed to diagnostic test manufacturers Read more about Meridian Agrees License Deal With Corixa[…]

Skyepharma Begins Requip Ocr Clinical

Skyepharma has initiated Phase III clinical trials of the oral controlled release formulation of GlaxoSmithKline‘s Requip (Ropinirole HCl). The new once daily formulation for Parkinson’s disease has been developed utilizing SkyePharma’s Geomatrix technology. Requip OCR is expected to simplify the treatment regime for patients using this drug, thus improving patient convenience and compliance. The company Read more about Skyepharma Begins Requip Ocr Clinical[…]